尊敬的投资者，

我们诚挚邀请您参加药明康德2026 年中期业绩交流电话会，参与会议请拨打下图电话号码或扫码注册。

Dear Investors,

WuXi AppTec cordially invites you to join our   2026 Interim Results   Webcast. We thank you for your interest and we sincerely hope you will join us.

关于药明康德

药明康德（股票代码：603259.SH/2359.HK）是全球医药及生命科学行业值得信赖的合作伙伴和重要贡献者，致力于通过提供一体化、端到端的新药研发和生产服务，推动全球医药健康创新。公司在亚洲、欧洲、北美等地均设有运营基地，依托独特的 "CRDMO" 业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来突破性的治疗方案。目前，公司的赋能平台正承载着来自全球 30 多个国家的合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现 " 让天下没有难做的药，难治的病 " 的愿景。更多信息，请访问公司网站：www.wuxiapptec.com

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO ( Contract Research, Development, and Manufacturing Organization ) platform. We are privileged to work alongside partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients — one collaboration at a time. Learn more at www.wuxiapptec.com.